SGMT Furnishes Press Release and Updated Investor Presentation

Rhea-AI Filing Summary

Sagimet Biosciences announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025 and has updated its investor slide presentation. The press release is furnished as Exhibit 99.1 and the slide deck as Exhibit 99.2.

Both exhibits are described in the report as being furnished rather than filed, and therefore are not deemed filed or incorporated by reference into other SEC filings except if expressly referenced. Company representatives will use the updated presentation in meetings with investors.

Positive

• Press release furnished announcing financial results for the quarter ended June 30, 2025 (Exhibit 99.1).
• Updated investor presentation made available for use in investor meetings (Exhibit 99.2).

Negative

• None.

Insights

Financial Analyst

TL;DR: Company furnished Q2 2025 results and updated investor slides; disclosure is routine and provides primary source material for investors.

The filing informs investors that the company has made its quarterly results public via a press release (Exhibit 99.1) and refreshed its investor presentation (Exhibit 99.2). Because the exhibits are furnished and not filed, the company limits certain statutory liabilities associated with filing. The disclosure itself is procedural; material content will depend on the exhibits' financial figures and commentary, which are not included here.

Corporate Governance Expert

TL;DR: Furnishing exhibits rather than filing is a common legal posture that retains control over incorporation-by-reference exposure.

From a governance and compliance standpoint, noting that the press release and presentation are furnished (not filed) clarifies the company's intent to provide information to the market while preserving the narrower liability profile associated with furnished disclosures. The report also documents that management will use the updated presentation in investor meetings, indicating coordinated external communications. This filing does not, by itself, disclose the financial results summarized in the press release.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

FAQ

What did Sagimet Biosciences (SGMT) disclose in this Form 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025 (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).

Are the press release and investor presentation filed with the SEC?

No. The document states both exhibits are furnished and are not deemed to be filed for certain legal purposes and are not incorporated by reference in other filings except by specific reference.

Where can investors find the exhibits referenced in the 8-K?

The filing identifies the press release as Exhibit 99.1 and the investor presentation as Exhibit 99.2; the exhibits are furnished with the Form 8-K.

Will company representatives use the updated materials publicly?

Yes. The filing states representatives will use the updated investor presentation in various meetings with investors from time to time.

Does this Form 8-K include the company's financial figures?

No. The Form 8-K states a press release announcing results was furnished as Exhibit 99.1, but the filing text itself does not include the financial figures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 08/13/2025 - 07:36 AM Learn about SEC filing dates

false 0001400118 0001400118 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

SAGIMET BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41742	20-5991472
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Sagimet Biosciences Inc.

155 Bovet Road, Suite 303,

San Mateo, California 94402

(Address of principal executive offices, including zip code)

(650) 561-8600

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Series A Common Stock, $0.0001 par value per share	SGMT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On August 13, 2025, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On August 13, 2025, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall Exhibit 99.2 furnished herewith be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Document
99.1		Press Release of Sagimet Biosciences Inc., dated August 13, 2025.
99.2		Investor Presentation of Sagimet Biosciences Inc., dated August 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Sagimet Biosciences Inc.
Date: August 13, 2025	By:	/s/ David Happel
		David Happel
		Chief Executive Officer